Shukra Medtech Q2 FY27 Net Profit Rises to ₹16.01 Crore

Shukra Medtech Limited reported standalone Q2 FY27 net profit of ₹16.01 crore, up from ₹2.38 crore a year earlier, as revenue from operations reached ₹44.20 crore. The result matters because the new Medtech business supplied ₹12.51 crore of quarterly segment revenue, while receivables and inventories absorbed much of the reported profit in cash terms.

What did Shukra Medtech report for Q2 FY27?

Shukra Medtech reported a sharp increase in standalone revenue and profitability for the quarter ended September 30, 2026. Revenue from operations rose to ₹44.20 crore from ₹5.88 crore in Q2 FY26, while net profit increased to ₹16.01 crore from ₹2.38 crore in the corresponding quarter a year earlier.

Profit before tax stood at ₹21.13 crore, compared with ₹0.20 crore in Q2 FY26. Earnings per share improved to ₹0.36 from ₹0.05. The Board of Directors approved the unaudited quarterly and half-yearly results on November 4, 2026.

The reported figures relate to standalone performance. The company operates through Pharmaceutical and Medtech segments, with the latter becoming an important contributor to its reported business mix during the quarter.

Which businesses contributed to Shukra Medtech's quarterly revenue?

The Pharmaceutical segment remained the larger reported business, generating ₹32.27 crore of revenue and ₹18.36 crore of segment profit in Q2 FY27. The Medtech segment reported revenue of ₹12.51 crore and profit before tax and interest of ₹3.10 crore for the quarter.

Medtech became effective as a segment from October 1, 2025. Its contribution in the September 2026 quarter indicates that the business was part of the company's operations throughout the comparable FY27 period, although no prior-year Medtech segment contribution was provided in the results summary.

The company was formerly called Shukra Pharmaceuticals Limited. Its name change to Shukra Medtech Limited took effect on October 12, 2026, after the quarter had ended. The revised name reflects the presence of both pharmaceutical and medical technology operations, but the financial results continue to show the two businesses as separate reportable segments.

Why was Shukra Medtech's operating cash flow lower than net profit?

Shukra Medtech generated ₹1.49 crore of net cash from operating activities in the half-year ended September 30, 2026, despite reporting a much higher quarterly net profit of ₹16.01 crore. The difference was linked to higher working-capital requirements rather than a reduction in reported profitability.

Trade receivables increased by ₹15.76 crore and inventories rose by ₹9.51 crore during the half year. These movements mean that a material part of the revenue and earnings recorded in the accounts had not yet been realised as cash collections by September 30. Inventory growth also represents funds committed to goods held for sale or use in operations.

For investors, this makes the pace of receivable collection and inventory movement relevant alongside profit growth. Strong accounting earnings and operating cash flow can diverge temporarily during periods of rapid expansion, but the disclosed working-capital increase remains a key part of the company's half-year financial position.

How did Shukra Medtech fund its balance-sheet expansion?

Shukra Medtech's total assets increased to ₹178.25 crore as of September 30, 2026, from ₹117.41 crore at the end of March 2026. The expansion came alongside significant investment in property, plant and equipment, for which cash outflow from investing activities was ₹15.38 crore during the half year.

Financing activities generated ₹18.91 crore, supported by proceeds from borrowings and the issuance of share capital. Current liabilities stood at ₹43.41 crore as of September 30, while the company also reported higher borrowings. The financing inflow helped support both the investment outflow and the funding needs created by higher receivables and inventories.

The financial position shows that the quarter's earnings growth was accompanied by an enlarged asset base and increased external funding. The results do not provide a separate timetable for conversion of receivables into cash or for the utilisation of the property, plant and equipment investment.

What do the Q2 results mean for investors?

The Q2 FY27 results show that Shukra Medtech's revenue base has expanded substantially from the year-earlier quarter, with both Pharmaceutical and Medtech operations contributing reported segment income. The Medtech segment's ₹12.51 crore revenue contribution gives the company a second operating line beyond its established pharmaceutical business.

At the same time, the financial statements highlight the distinction between profit and cash generation. Net profit for the quarter was ₹16.01 crore, whereas half-year operating cash flow was ₹1.49 crore after the increase in receivables and inventory. This makes balance-sheet movements important when assessing the quality and funding requirements of the reported growth.

The board's approval of the unaudited results, together with the disclosed segment data and cash-flow statement, provides the immediate financial record for the September quarter. The company has not disclosed a forward revenue target, margin target, or detailed outlook in the information provided.

Conclusion

Shukra Medtech delivered materially higher standalone Q2 FY27 revenue, profit before tax and net profit, led by its Pharmaceutical business and a ₹12.51 crore contribution from Medtech. However, the half-year cash-flow data shows that expansion also required considerable investment in receivables, inventory and property, plant and equipment.

The next financial updates will be relevant for evidence of cash conversion, particularly changes in trade receivables and inventory, as well as the level of borrowings and financing needs. Investors can also track whether the Medtech segment maintains or expands its contribution to reported revenue and segment profit.